The top ten priorities for research into epilepsy were established by the UK epilepsy community, including people living with and affected by epilepsy, healthcare professionals and patient groups though a James Lind Alliance Priority Setting Partnership.1,2Â
See the priorities ranked 11–25
Epilepsy syndromes: What are the initial and add-on AEDs of choice in the treatment of the epilepsy syndromes with onset in childhood, for example, myoclonic-astatic epilepsy and Dravet syndrome? Go to NICE
Risk prediction tool for all-cause epilepsy-related death: Development of a risk prediction tool to detect all-cause mortality including sudden unexpected death in epilepsy (SUDEP) in people with epilepsy or those who have had a single seizure, and an external validation of a risk prediction tool to detect the probability of epilepsy-related death. Go to NICE
Complex epilepsy syndromes: What antiseizure therapies (alternative or add-on) are effective in the treatment of complex epilepsy syndromes (that is, Dravet syndrome, Lennox–Gastaut syndrome, infantile spams syndrome and epilepsy with myoclonic-atonic seizures [Doose syndrome]) when first-line therapy is unsuccessful or not tolerated? Go to NICE
Psychological treatments: What is the cost-effectiveness of providing tailored psychological treatments for people with epilepsy? Go to NICE
Antibody testing: What immunomodulation strategies are effective in people with defined autoimmune epilepsy syndromes? Go to NICE
Digital health technologies: What is the clinical and cost effectiveness of digital health technologies in people with epilepsy? Go to NICE
Vagus nerve stimulation: What is the effectiveness of vagus nerve stimulation in treating epilepsy (including people with learning disabilities as a subgroup)? Go to NICE
Ketogenic diets: What is the short-term and long-term clinical and cost effectiveness of ketogenic diets in adults and children with drug-resistant epilepsy, and what factors affect the long-term maintenance and tolerability of ketogenic diets? Go to NICE
Monitoring antiseizure medications in women and girls: What is the clinical and cost effectiveness of therapeutic drug monitoring in girls, young women and women with epilepsy? Go to NICE
Newly diagnosed seizures (focal and generalised) – monotherapy: How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy?
CBD: What is the clinical and cost effectiveness of CBD in epileptic disorders in children, young people and adults? Go to NICE
Does the addition of THC to CBD have an effect on seizure frequency, brain structure and neuropsychological performance when compared with both CBD alone and placebo in epileptic disorders in children, young people and adults? Go to NICE
AEDs and pregnancy: What is the malformation rate and longer term neurodevelopmental outcome of children born to mothers who have taken AEDs during pregnancy? Go to NICE
Antiseizure medication for repeated or cluster seizures: What antiseizure medications (monotherapy or add-on) are effective in the treatment of repeated or cluster seizures? Go to NICE
Risk prediction tool for second seizure: Development of a risk prediction tool for second seizures in people with a single seizure, and an external validation of a risk prediction tool to detect the probability of a second seizure in people with a single seizure at baseline. Go to NICE
Infantile spasms: Does treatment response relate to cause in infantile spasms? Does early treatment success in seizure control and resolution of the hypsarrhythmic EEG influence the long-term developmental and cognitive outcomes more than the underlying cause of the spasms? Go to NICE
Treatment of convulsive status epilepticus (that is, not just refractory): What is the most effective and safest AED to treat: